Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Chemotherapy For Unresectable Locally Advanced Colon Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03970694
Recruitment Status : Recruiting
First Posted : May 31, 2019
Last Update Posted : May 31, 2019
Sponsor:
Collaborators:
First Affiliated Hospital, Sun Yat-Sen University
Sixth Affiliated Hospital, Sun Yat-sen University
Fujian Medical University Union Hospital
Second Affiliated Hospital, School of Medicine, Zhejiang University
Nanfang Hospital of Southern Medical University
Tongji Hospital
Information provided by (Responsible Party):
Yuan-hong Gao, Sun Yat-sen University

Brief Summary:

A. Background and purpose:

Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for unresectable locally advanced colon cancer: an open, multi-centered, randomize controlled phase 3 trial.

Colorectal cancer is one of the most common malignant tumors, the morbidity and mortality rate are both in rising trend. 10-23% newly diagnosed colon cancer is at locally advanced stage and surgically unresectable. For this subgroup, treatment guidelines recommend neoadjuvant chemotherapy with or without targeted therapy. However, less than 50% patients could convert into R0 resectable, therapeutic effect is unsatisfactory, 5-year overall survival rate is only 12.5%-45.7%.[JCO,2010] Since 2006, neoadjuvant chemoradiotherapy has been a recommendation as standard treatment for locally advanced rectal cancer, and has been widely applied to clinical use. As for locally advanced colon cancer, it still lacks evidence to support whether neoadjuvant chemoradiotherapy is a beneficial option. There are only several articles about locally advanced colon cancer undertaking neoadjuvant chemoradiotherapy before surgery through Pubmed research, including 3 case reports, 1 abstract and 5 clinical researches with a small sample size, 3 of which are from the investigator's study group.

The investigators recently reported clinical data about therapeutic effect of 60 unresectable locally advanced colon cancer cases and the results were exciting. According to the results, through neoadjuvant chemoradiotherapy, R0 resection rate is 86%, local recurrence rate is 10.2%, 3-year OS and 5-year OS are 76.7% and 66.6%, respectively. [Onco Targets Ther, 2018] "Colorectal cancer diagnoses and treatment guidelines" written by Chinses Society of Clinical Oncology (ver. 2017, 2018), suggested that neoadjuvant chemoradiotherapy was an optional treatment strategy or secondary recommended treatment strategy. In a word, the investigators' result was referred as revisory basis of the guideline [CJC,2016], with a relatively low level of evidence in evidence-based medicine.

This phase 3 clinical trial mainly aims to acquire a higher level of evidence in evidence-based medicine on the subject about neoadjuvant chemoradiotherapy as a treatment strategy to unresectable locally advanced colon cancer, and the ultimate goal is to rewrite the International treatment guidelines of locally advanced colorectal cancer.

B. Research Content:

  1. . Research Object: Patients who newly diagnosed unresectable locally advanced colon cancer. Including: 1. tumor infiltrates through the intestinal wall and adheres to tissues and organs around the colon(T4b), imaging assesses that R0 resection is unachievable. 2. Pericolonic lymph node involvement is closely adjacent to the large abdominal vessels, imaging assesses that lymphadenectomy is difficult. 3. Surgical exploration indicates that R0 resection is not achievable. 4. In initial diagnosis, surgeon evaluates the need for extensive multi-organ combined resection and expected to damage the organs, which would seriously affect the postoperative quality of life.
  2. . Main research indicator: 5-year overall survival rate
  3. . Secondary research indicators: 1. R0 resection rate 2. 3-year tumor-free survival rate
  4. . Research groups assignment: 1. Research group: Neoadjuvant chemoradiotherapy group; 2. Control group: Neoadjuvant chemotherapy group.
  5. . Sample calculation: Calculation is based on the main research indicator: 5-year survival rate. Based on α=0.05(bilateral), β=0.20(unilateral), 5-year OS improves from 45% in control group to 65% in research group, 4-year period, 5-year follow-up. Research group and control group should at least enroll 74 and 75 qualified cases, respectively, a total of 149 cases, with an expected delisting rate of 20%, the total sample size is 186, 93 cases for each group.
  6. . Research protocols:

1. Research group: Neoadjuvant chemoradiotherapy(XELOX * 4 + radiotherapy)→ Surgery (if possible) → post-surgery chemotherapy.

2. Control group: Neoadjuvant chemotherapy(XELOX * 4)→ Surgery (if possible) → post-surgery chemotherapy.

Chemotherapy strategy: XELOX: oxaliplatin 130mg/m2, iv drip, d1, every 3 weeks; capecitabine 1,000mg/m2, bid, d1-d14, every 3 weeks. Concurrent chemotherapy: mXELOX: which oxaliplatin is 100mg/m2.

Radiotherapy strategy: IMRT, 6-8MV X-ray; GTV 45-50Gy/25F, 1.8-2.0Gy/F; CTV 42.5-45Gy/25F, 1.7-1.8Gy/F; Actual delivery dose should be adjusted according to max tolerance dose of organs at risk, but the delivery dose of GTV and CTV must within the required range.

Surgery: Reexamination is performed 5 weeks after radiotherapy for research group and 2 weeks after the fourth period of chemotherapy, surgery is performed in 6-12 weeks after neoadjuvant treatment.


Condition or disease Intervention/treatment Phase
Colon Cancer Radiation: Radiotherapy Drug: oxaliplatin+capecitabine Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 186 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Research group: Neoadjuvant chemoradiotherapy group Control group: Neoadjuvant chemotherapy group
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Chemotherapy For Unresectable Locally Advanced Colon Cancer: An Open, Multi-centered, Randomize Controlled Phase 3 Trial.
Actual Study Start Date : May 11, 2019
Estimated Primary Completion Date : January 2028
Estimated Study Completion Date : December 2028

Arm Intervention/treatment
Experimental: Neoadjuvant chemoradiotherapy group
Neoadjuvant chemoradiotherapy(XELOX * 4 + radiotherapy)→ Surgery (if possible) → post-surgery chemotherapy.
Radiation: Radiotherapy
Since 2006, neoadjuvant chemoradiotherapy has been a recommendation as standard treatment for locally advanced rectal cancer, and has been widely applied to clinical use. As for locally advanced colon cancer, it still lacks evidence to support whether neoadjuvant chemoradiotherapy is a beneficial option.We recently reported clinical data about therapeutic effect of 60 unresectable locally advanced colon cancer cases and it was exciting. According to our results, through neoadjuvant chemoradiotherapy, R0 resection rate is 86%, local recurrence rate is 10.2%, 3-year OS and 5-year OS are 76.7% and 66.6%, respectively."Colorectal cancer diagnoses and treatment guidelines" written by Chinses Society of Clinical Oncology (ver. 2017, 2018), suggested that neoadjuvant chemoradiotherapy was an optional treatment strategy or secondary recommended treatment strategy.

Drug: oxaliplatin+capecitabine
Colorectal cancer is one of the most common malignant tumors, the morbidity and mortality rate are both in rising trend. 10-23% newly diagnosed colon cancer is at locally advanced stage and surgical unresectable. For this subgroup, treatment guidelines recommend neoadjuvant chemotherapy with or without targeted therapy.

Neoadjuvant chemotherapy group
Arm Type: control. Neoadjuvant chemotherapy(XELOX * 4)→ Surgery (if possible) → post-surgery chemotherapy.
Drug: oxaliplatin+capecitabine
Colorectal cancer is one of the most common malignant tumors, the morbidity and mortality rate are both in rising trend. 10-23% newly diagnosed colon cancer is at locally advanced stage and surgical unresectable. For this subgroup, treatment guidelines recommend neoadjuvant chemotherapy with or without targeted therapy.




Primary Outcome Measures :
  1. 5-year overall survival rate [ Time Frame: 5 years after treatment ]
    The percentage of patients survive 5 years after treatment.


Secondary Outcome Measures :
  1. R0 resection rate [ Time Frame: an average of 6 to 12 weeks after surgery ]
    The percentage of patients whose post-operative pathology indicate no tumor residue is observed under microscope

  2. 3-year regression-free survival rate [ Time Frame: 3 years after treatment ]
    The percentage of patients have no tumor regression after treatment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histology confirms colonic adenocarcinoma.
  • The distance from the lower edge of the tumor to the anal edge is greater than or equal to 15cm (from sigmoid colon to ileocecal region)
  • Preoperative staging (Satisfying any one out of four conditions below)

    1. Tumor infiltrates through the intestinal wall and adheres to tissues and organs around the colon(T4b), imaging assesses that R0 resection is unachievable.
    2. Pericolonic lymph node involvement is closely adjacent to the large abdominal vessels, imaging assesses that lymphadenectomy is difficult.
    3. Surgical exploration indicates that R0 resection is not achievable.
    4. In initial diagnosis, surgeon evaluates the need for extensive multi-organ combined resection and expected to damage the organs, which would seriously affect the postoperative quality of life.
  • No obvious signs of intestinal obstruction, or obstruction has been relieved after proximal enterostomy.
  • Preoperative CT/MRI/PET-CT has ruled out distant metastasis.
  • Blood and biochemical indexes achieve standard (Satisfying all three conditions below):

    1. Routine blood test: WBC>4000/mm3; PLT>100000/mm3; Hb>6g/dl.
    2. Liver function: SGOT, SGPT and Bilirubin are less than or equal to 1.5 times normal upper limit.
    3. Renal function: Creatinine is less than or equal to 1.5 times normal upper limit.

Exclusion Criteria:

  • History: Has colon surgery history; Received chemotherapy or biotherapy in the past 5 years; Received radiotherapy in treatment field.
  • Infectious disease: HIV infection history; Active phase chronic hepatitis B or hepatitis C (high copies of virus DNA); Other serious active clinical infection.
  • Diagnosed as stage I colon cancer.
  • Extraperitoneal distant metastasis is positive in pre-operative stage.
  • Dyscrasia or organ decompensation.
  • Received radiation therapy in abdominal or pelvic regions.
  • Multiple primary cancer.
  • Epileptic seizures requiring medical treatment.
  • Other malignant tumor history in the past 5 years (except endocervical cancer in situ or skin basal cell carcinoma which had been cured)
  • Chronic inflammatory colorectal disease, unrelieved ileus.
  • Drug abuse, has medical, psychological or social condition that might affect research results.
  • Allergic to research-related drugs.
  • Any unstable situation that might endanger patient's safety or compliance.
  • Pregnant, lactating woman patient or fertile but lacks adequate contraceptives.
  • Refuses to sign informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03970694


Contacts
Layout table for location contacts
Contact: Yuan-hong Gao, M.D 86-020-87343491 gaoyh@sysucc.org.cn
Contact: Wei-wei Xiao, M.D 8602087343491 ext 8602087343491 xiaoww@sysucc.org

Locations
Layout table for location information
China, Guangdong
Sun Yat-sen University Cancer Center Recruiting
Guangzhou, Guangdong, China, 510060
Contact: Yuan-hong Gao, M.D    86-020-87343491    gaoyh@sysucc.org.cn   
Contact: Wei-wei Xiao, M.D    86-020-87343491    xiaoww@sysucc.org   
Principal Investigator: Yuan-hong Gao, M.D         
Sub-Investigator: Li-ren Li, M.D         
Sub-Investigator: Zhen-hai Lu, M.D         
Sub-Investigator: Zhi-qiang Wang, M.D         
Sub-Investigator: Feng Wang, M.D         
Sub-Investigator: Zhi-fan Zeng, M.D         
Sub-Investigator: Wei-wei Xiao, M.D         
Sub-Investigator: Hui Chang, M.D         
Sponsors and Collaborators
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University
Sixth Affiliated Hospital, Sun Yat-sen University
Fujian Medical University Union Hospital
Second Affiliated Hospital, School of Medicine, Zhejiang University
Nanfang Hospital of Southern Medical University
Tongji Hospital
Investigators
Layout table for investigator information
Study Chair: Yuan-hong Gao, M.D Sun Yat-sen University

Publications:

Layout table for additonal information
Responsible Party: Yuan-hong Gao, Professor, Sun Yat-sen University
ClinicalTrials.gov Identifier: NCT03970694     History of Changes
Other Study ID Numbers: 2018-FXY-194
First Posted: May 31, 2019    Key Record Dates
Last Update Posted: May 31, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Yuan-hong Gao, Sun Yat-sen University:
Neoadjuvant chemoradiotherapy
Colon Cancer
Initial Diagnosed Unresectable Locally Advanced Stage
Phase 3 Clinical Trial
Additional relevant MeSH terms:
Layout table for MeSH terms
Colonic Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Colonic Diseases
Capecitabine
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Oxaliplatin
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents